Danish drugmaker Novo Nordisk is partnering with ChatGPT’s parent company, OpenAI, to bring ‘better treatment options’ for patients. The development comes as pharma companies are increasingly relying on AI to boost R&D and operations.
Race for AI-developed drugs heats up: Wegovy-maker Novo Nordisk ties up with OpenAI after rival Eli Lilly seals deal
